Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.
Videos
Melina E. Marmarelis, MD, reports the rationale and key findings from the Chrysalis-2 trial of patients with EGFR-mutated advanced non–small cell lung cancer.
Eytan M. Stein, MD, defines Menin inhibition and its role in the leukemia space.
Shannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.
Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.
Dr Nizar Tannir describes data presented at ASCO 2022 from EVEREST investigating everolimus vs placebo for patients with high-risk disease.
Experts discuss the use of pembrolizumab as an adjuvant therapy in advanced clear cell RCC.
Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.
Deena Mary Atieh Graham, MD, discusses the treatment options for a breast cancer diagnosis and explains how patients are affected after treatment.
Dr Bardia talks about the role of biomarker testing and provides an overview of factors which may contribute to a clinician’s choice of treatment strategy for patients with ER+/HER- mBC.
Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.
Rupesh R. Kotecha, MD, discusses a newer radiation modality known as pulse reduced dose rate radiation therapy.
Cristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.
Centering discussion on the first patient case of BPDCN, expert panelists highlight various assessment tools that may help overcome barriers to an early diagnosis.
Shared insight on methods to identify blastic plasmacytoid dendritic cell neoplasm followed by updated classifications from the World Health Organization.
Broad perspective on diagnosis of the myeloproliferative neoplasms via optimal workup and molecular testing.
In this companion article, Dr Mark Socinski provides insights into the use of trilaciclib for the management of chemotherapy-induced myelosuppression in patients being treated for extensive -stage small cell lung cancer.
A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.
Carolyn Owen, MD, discusses how the treatment landscape has shifted in chronic lymphocytic leukemia.
Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.
Gene G. Finley, MD, explains the use of conventional chemotherapy in the small cell lung cancer space.
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.
Srdan Verstovsek, MD, PhD, discusses the increased thrombotic risk and management for patients with essential thrombocythemia.
Andreas Saltos, MD, discusses what he anticipates future research will examine regarding treatment options for EGFR and KRAS-mutated non-small cell lung cancer.
Jamie Brett discusses the similarities and differences between ESR1 mutations and fusions and why they are grouped together.
Aime T. Franco, PhD, discusses how recent research has explored the difference between pediatric thyroid cancer and adult thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.
Mark Markowski, MD, PhD, discusses the results of a phase 1b/2 study examining treatment with sabizabulin in patients with metastatic castration-resistant prostate cancer.
Matthew Ingham, MD, discusses the unique biology of uterine sarcomas.
Dr Scott Tykodi explains the scenarios in which he would switch a patient to another regimen without dose reduction first.